Data investigation
Newer Is Not Stronger
Survodutide has a new mechanism and phase 3 results in the NEJM. It produced 13.0% weight loss at 76 weeks, and its higher dose caused gut side effects in nearly nine of ten participants while losing only 0.8 points more weight than the lower dose.
Survodutide is a new drug with a new mechanism, and its phase 3 results are in the New England Journal of Medicine.[1] It produced 13.0% weight loss at 76 weeks. Its higher dose caused gut side effects in nearly nine of ten participants and lost barely more weight than the lower one (13.0% against 12.2%). A newer drug is not necessarily a stronger one. Drugs still in development are harder still to rank, because the most striking early figure among them comes from a four-week study.
What it is and what it did
Survodutide activates the GLP-1 receptor and the glucagon receptor, a different second target from tirzepatide’s GIP. Glucagon is best known for raising blood sugar, and the rationale for stimulating it deliberately is that it also increases energy expenditure and acts on the liver. The full picture, including the diabetes trial, the liver data and heart rate, is in survodutide: what the phase 3 evidence shows.
The trial randomized 725 adults with a BMI of 30 or above, or 27 with a weight-related complication and no diabetes, to survodutide at 3.6 mg, 6.0 mg, or placebo for 76 weeks, analyzed on the conservative treatment-regimen estimand.
| 3.6 mg | 6.0 mg | Placebo | |
|---|---|---|---|
| Weight change | −12.2% (95% CI −13.6 to −10.8) | −13.0% (−14.4 to −11.6) | −5.4% (−6.9 to −4.0) |
| Reached at least 5% loss | 72.6% | 71.9% | 46.3% |
| Gastrointestinal adverse events | 80.9% | 89.7% | 47.9% |
No deaths occurred, and all comparisons against placebo reached P<0.001.
Two doses, one result, different costs
A second phase 3 trial, in 752 adults who also had type 2 diabetes, has since been published. At 76 weeks the two doses produced −8.2% and −9.8% against −3.9% on placebo, and gastrointestinal adverse events rose from 72.8% to 77.7% with the higher dose, against 38.6% on placebo.[2] The two trials enrolled different people, so their headline numbers do not compare with each other. What repeats is the pattern inside each one: a small step between doses, paid for in side effects.
That is the same pattern we found in a trial of a different drug, where tripling the dose produced no additional blood sugar benefit (see the dose that stopped helping). Dose-response curves flatten, and they flatten on efficacy before they flatten on harm.
Read the placebo column before the headline
The placebo group lost 5.4%, and 46.3% of them reached a 5% reduction. That is a large placebo response: nearly half of people receiving no active drug hit the threshold the trial was built around.
The drug’s own contribution is about 7.6 percentage points, not 13.
Everyone in the trial received counseling for lifestyle modification, and 76 weeks of structured attention produces real weight loss on its own. Quoting −13.0% without the placebo arm hides that about 40% of it (5.4 points) also happened on placebo, and that is the number that will circulate.
The comparison we are not going to make
There is one place a fair comparison exists. A network meta-analysis of 262 trials places every drug against a common reference, which is what makes them comparable (see what 262 trials say together). That analysis is where a ranking belongs, not here.
What can be said from this trial alone: survodutide works, it works substantially better than placebo, and the higher of its two doses adds side effects while adding little weight loss.
Why it is still worth watching
- The mechanism is new. Glucagon receptor agonism is not GIP, and its effects on the liver and on energy expenditure may show up on endpoints this trial did not measure.
- Weight is not the only outcome that matters. The drug with the most weight loss is not the drug with the mortality evidence, which is set out in the head-to-head.
- It is unapproved. No label, no manufacturer of record, and peptide sellers are already marketing it. FDA has warned some of them, following the pattern documented in retatrutide’s phase 3 and the gray market.
- Funded by Boehringer Ingelheim, which is developing it.
Frequently Asked Questions
References
- 1.le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity The New England Journal of Medicine. 2026. PMID: 42253238.
- 2.Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes The New England Journal of Medicine. 2026. PMID: 42820639.
Compare the sellers
Related research
What Tripling the Dose Buys
A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.
7 min read
More Effect Without More Side Effects
Almost every result in this field trades benefit against harm. Adding cagrilintide to semaglutide produced 6.5 percentage points more weight loss with gut side effects at 53% against 51%.
6 min read
One Injection Instead of Twenty-Eight
Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.
6 min read
What 262 Trials Say Together
262 trials, 99,791 people, 19 drugs, every result graded. Three of its findings cut against how this field is described, starting with the fact that the drug with the mortality evidence is not the one that takes off the most weight.
9 min read
Another Molecule You Cannot Buy
A dual agonist reported 14.7% weight loss in thirteen weeks. The drug is approved nowhere, and a thirteen-week figure sits on the steepest part of a curve that flattens.
6 min read
The First Pill-Versus-Pill Trial
Orforglipron beat oral semaglutide on HbA1c at every dose pairing in 1,698 adults, and produced twice the dropouts and three times the heart rate rise. Both halves are the result.
8 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →